Please use this identifier to cite or link to this item:
Title: Does long-term phenytoin have a place in Dravet syndrome?
Austin Authors: Zographos, George A;Russ-Hall, Sophie J;Scheffer, Ingrid E 
Affiliation: Epilepsy Research Centre
Medicine (University of Melbourne)
Issue Date: Dec-2022
Date: 2022
Publication information: Annals of Clinical and t Translational Neurology 2022; 9(12)
Abstract: Anti-seizure medications that block sodium channels are generally considered contraindicated in Dravet syndrome. There is, however, considerable debate about the sodium-channel blocker phenytoin, which is often used for status epilepticus, a frequent feature of Dravet syndrome. We describe four patients with Dravet syndrome in whom long-term phenytoin therapy reduced seizure frequency and duration. In two patients, phenytoin produced prolonged periods without status epilepticus for the first time. Attempting to wean phenytoin in all patients after 1 to 20 years of use resulted in seizure exacerbation. Reintroducing phenytoin improved seizure control, suggesting phenytoin is beneficial in some patients with Dravet syndrome.
DOI: 10.1002/acn3.51684
ORCID: 0000-0002-8768-9757
Journal: Annals of Clinical and t Translational Neurology
Start page: 2036
End page: 2040
PubMed URL: 36314457
ISSN: 2328-9503
Type: Journal Article
Subjects: Phenytoin/pharmacology
Phenytoin/therapeutic use
Epilepsies, Myoclonic/drug therapy
Status Epilepticus/drug therapy
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 28, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.